Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer
Women's Triple-Negative First-Line Study: A Phase II Trial of Mirvetuximab Soravtansine in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy (NACT), Including a Lead-In Cohort to Establish Activity in Patients With Metastatic TNBC
Sponsor: M.D. Anderson Cancer Center
This PHASE2 trial investigates Anatomic Stage II Breast Cancer AJCC v8 and Anatomic Stage IIA Breast Cancer AJCC v8 and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 13 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Oct 2020 — Dec 2020 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Feb 2020 — Oct 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2018 — Sep 2019 [monthly]
Recruiting PHASE2
-
Oct 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Aug 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Jun 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .